Wegovy Side Effects in Pregnancy: What the Guidance Actually Says

Why regulators say Wegovy should not be used in pregnancy

The position against using Wegovy in pregnancy comes directly from its licensed prescribing information and from MHRA guidance, not from caution alone. Animal reproduction studies with semaglutide showed adverse effects on foetal development at doses relevant to human exposure, and those findings were sufficient for regulators to withhold a safety recommendation for human pregnancy. There are no adequately controlled studies in pregnant women, and the absence of reassuring human data means the precautionary position stands. The NHS patient information on semaglutide is unambiguous: do not take semaglutide if you are pregnant.

GLP-1 receptor agonists slow gastric emptying and affect appetite signalling in ways that, during pregnancy, could theoretically affect nutrient absorption and weight gain at a time when both matter for the developing baby. That mechanism adds biological plausibility to the regulatory caution, and the semaglutide pregnancy risk page explains in detail what the animal findings showed and why regulators treated them as sufficient grounds for precaution. What is known is taken seriously.

If you are reading this because you discovered a pregnancy while already on Wegovy, a once-weekly injectable treatment licensed for chronic weight management in adults, that is an unsettling position. The practical guidance is to stop the medicine and contact your GP or midwife. Accidental early exposure is not the same as prolonged use, and your clinical team can give you properly contextualised information about your individual situation. For a fuller look at whether Wegovy is safe during pregnancy, including what the evidence and regulatory guidance actually cover, that page goes through the data in more detail.

Contraception, wash-out periods, and planning ahead

For anyone on Wegovy who is not yet pregnant but thinking about it, the wash-out period matters. The MHRA advises that women use effective contraception while taking GLP-1 medicines and for a specified period after stopping before trying to conceive. The exact duration for semaglutide is set out in the medicine's summary of product characteristics and should be confirmed with your prescriber, it is not something to estimate. Do not stop Wegovy, wait a weekend, and assume the medicine has cleared your system.

There is an additional practical point for women using oral contraceptives. Unlike tirzepatide (Mounjaro), which is associated with a documented reduction in oral contraceptive absorption during the early dose-escalation period, the NHS notes there is no equivalent evidence that semaglutide reduces pill effectiveness in the same way. Even so, any significant gastrointestinal side effects (persistent vomiting in particular) can theoretically affect how reliably an oral contraceptive is absorbed. This is worth discussing with your GP, especially during the early weeks when nausea is most common.

The timing of when to have this conversation matters too. Waiting until you are ready to start trying tends to be too late for a comfortable handover, including any bridging support for weight management during and after the wash-out. Some patients find it useful to raise the subject at their next repeat review, even if conception is months away. Our prescribers at nume can discuss this as part of a regular clinical check-in. Detailed questions about fertility planning and contraception belong with your GP or a specialist who knows your full history.

What is still uncertain, and who to talk to

The gap in the evidence is real and worth naming plainly. Because GLP-1 medicines are relatively new to widespread use in weight management, and because pregnancy studies in humans are both ethically complex and practically slow to generate, there are things regulators genuinely do not yet know. Long-term follow-up data on pregnancies where exposure occurred in the first trimester (before a pregnancy was confirmed) is limited. Registry studies are ongoing. The MHRA Drug Safety Update index is where new communications on this topic will appear if the regulatory position changes; it is worth checking if you have specific concerns.

Uncertainty does not mean the risk is confirmed, it means the risk cannot be excluded. That distinction matters, but it does not change the practical guidance, which is clear. For the broader picture of side effects outside pregnancy, the Wegovy side effects overview covers the full licensed profile including gastrointestinal effects, pancreatitis signals, and what to watch for at each stage of treatment. If your question is more specifically about whether Wegovy is safe to use if you are pregnant or planning to become pregnant, that page addresses the question directly using the same regulatory sources, and if you want to understand whether semaglutide is safe in pregnancy more broadly, including what the animal data and emerging registry evidence actually show, that is covered there too.

Your first port of call if you are pregnant or planning a pregnancy while on Wegovy is your GP or midwife. They hold your full medical record, can coordinate with your maternity team, and can advise on weight management strategies that are appropriate during pregnancy. Wegovy is a prescription medicine assessed case by case; if you have questions about your treatment status, our support team is available seven days a week.